Physician profile
Amy L Egan
NPI 1861702151
$1,578.54
in general payments reported to CMS, 2019-2025
15 companies · $835 in 2025
The $835 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $206 · 2023: $202 · 2024: $335 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $616.04 | 2022-2025 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $316.82 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $200.27 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $152.85 | 2022-2024 | Dupixent |
| Jazz Pharmaceuticals INC. | $62.81 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.77 | 2022-2023 | Ofev |
| Pfizer INC. | $34.40 | 2025 | |
| Beone Medicines USA, INC. | $23.94 | 2025 | Brukinsa |
| Invivyd INC | $18.34 | 2025 | Pemgarda |
| Viatris Specialty LLC | $17.60 | 2025 | Yupelri |
| Verona Pharma, INC. | $17.52 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $16.55 | 2024 | Inspire |
| United Therapeutics Corporation | $15.40 | 2024 | Tyvaso |
| Mylan Specialty L.P. | $13.74 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.